ERBB2 and breast cancer: The current treatment of HER2-positive BC primarily consists in the well known and clinically efficient monoclonal antibodies trastuzumab, Trastuzumab-DM1 (TDM1-Herceptin®) and pertuzumab (Perjeta®).